In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer (Business Wire)
- Task force updates ERCP quality metrics (GI & Hepatology News)
- New simulator mimics real tissue for safer endoscopic cancer surgery training (Medical Xpress)
- 5 GI leaders on what’s changing in colonoscopy (Becker’s GI & Endoscopy)
- Scientists create a luminous pill with biosensors meant to replace colonoscopies (Earth.com)
- FUJIFILM 800 Series Duodenoscopes Now Compatible with CE Mark Approved ULTRA GI Cycle (Fujifilm)
- Private Equity’s Healthcare Boom Is Getting More Crowded (MedCity News)
- Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab (Reuters)
